<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using WebFilings 1 -->
		<!-- Copyright 2008-2014 WebFilings LLC. All Rights Reserved -->
		<title>RBC 8K 2014_01_08</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<a name="s3949C2CAF52780E5EBDD07994109E3D9"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, DC 20549</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">FORM 8-K</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of earliest event reported): </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">January&#160;8, 2014</font><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td width="34%"></td><td width="33%"></td><td width="33%"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________________</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">RBC Life Sciences, Inc.</font><font style="font-family:inherit;font-size:10pt;">______________________</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter) </font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">NEVADA</font><font style="font-family:inherit;font-size:10pt;">_______ </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of incorporation)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">000-50417</font><font style="font-family:inherit;font-size:10pt;">_________ </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">File Number)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">_______</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">91-2015186</font><font style="font-family:inherit;font-size:10pt;">________ </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(IRS Employer </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">2301 CROWN COURT, IRVING, TEXAS </font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">75038</font><font style="font-family:inherit;font-size:10pt;">_____________</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code __________</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">972-893-4000</font><font style="font-family:inherit;font-size:10pt;">______________ </font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________</font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">N/A</font><font style="font-family:inherit;font-size:10pt;">____________________________</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Former name or former address, if changed since last report) </font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td width="5%"></td><td width="95%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[ ]</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><a name="sA5E10EBD39E05A9CF3F20799413BCE95"></a><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><br><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2014, RBC Life Sciences, Inc. (the "Company) and Richard S. Jablonski entered into an Employment Agreement (the "Jablonski Agreement") providing for compensation and related benefits to Mr. Jablonski in connection with his employment as Vice President - Finance and Chief Financial Officer of the Company.  Under the Jablonski Agreement, Mr. Jablonski will receive an annualized base salary of $200,000 and will be eligible to participate in any discretionary cash incentive plan which may be adopted by the Compensation Committee of the Company's Board of Directors.  In addition, Mr. Jablonski will receive a supplemental benefit payment of $1,000 each month for the term of the Jablonski Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Jablonski Agreement is for an initial term beginning on January 1, 2014 and ending on December 31, 2014.  The term of the Jablonski Agreement will be automatically renewed for an additional one-year term upon expiration of the initial term and each subsequent term thereafter, unless either the Company or Mr. Jablonski gives written notice to the other party at least thirty (30) days prior to the last day of the then current term of the Jablonski Agreement. Upon termination of Mr. Jablonski's employment by the Company without Cause, by Mr. Jablonski for Good Reason (as such terms are defined in the Jablonski Agreement), or by non-renewal of the Jablonski Agreement by the Company, Mr. Jablonski shall be paid an amount equal to the greater of his monthly base salary through the last day of the then current term, or his monthly base salary for a period of six (6) months, plus a lump sum payment equal to his accrued, unused vacation and personal time off, not to exceed 520 hours.  For 12 months following the termination of his employment by the Company or in the event the Company elects not to renew the Jablonski Agreement, Mr. Jablonski will be prohibited from attempting to solicit the Company's existing customers and employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On January 8, 2014, the Company and Kevin B. Young entered into an Employment Agreement (the "Young Agreement") providing for compensation and related benefits to Mr. Young in connection with his employment as Vice President of Sales of the Company.  Under the Young Agreement, Mr. Young will receive an annualized base salary of $160,000 and will be eligible  to participate in any discretionary cash incentive plan which may be adopted by the Compensation Committee of the Company's Board of Directors.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Young Agreement is for a term beginning on January 1, 2014 and ending on December 31, 2014.  Upon termination of employment by the Company without Cause or by Mr. Young for Good Reason (as such terms are defined in the Young Agreement), Mr. Young shall be entitled to receive his monthly base salary for a period of three months and a lump sum payment equal to his accrued, unused vacation and personal time off, not to exceed 520 hours.  For 12 months following the termination of his employment by the Company or in the event the Company elects not to renew the Young Agreement, Mr. Young will be prohibited from attempting to solicit the Company's existing customers and employees.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><a name="sA43FD3902BDEE5B70847079941635496"></a><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: </font><font style="font-family:Times New Roman;font-size:10pt;color:#000000;text-decoration:none;">January&#160;9, 2014</font><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;text-indent:336px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:29.4921875%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td width="100%"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">RBC Life Sciences, Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By: </font><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">/s/ Richard S. Jablonski</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Name:  Richard S. Jablonski</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Title:  Vice President - Finance &amp; Chief Financial Officer</font></div></td></tr></table></div></div><div style="line-height:120%;padding-left:384px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><br><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
[{"type": "8-K", "sequence": "1", "filename": "rbc8k2014_01x08.htm", "description": "8-K", "secsgml_size_bytes": 20079}]
{"company-data": {"conformed-name": "RBC LIFE SCIENCES, INC.", "cik": "0000830052", "assigned-sic": "5190", "irs-number": "752224643", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-50417", "film-number": "14517744"}, "business-address": {"street1": "2301 CROWN COURT", "city": "IRVING", "state": "TX", "zip": "75038", "phone": "9728934000"}, "mail-address": {"street1": "2301 CROWN COURT", "city": "IRVING", "state": "TX", "zip": "75038"}, "former-company": [{"former-conformed-name": "ROYAL BODYCARE INC/NV", "date-changed": "19991115"}, {"former-conformed-name": "GLOBENET INTERNATIONAL I INC", "date-changed": "19970515"}, {"former-conformed-name": "MIGHTY POWER USA INC", "date-changed": "19960306"}]}
RBC 8K 2014_01_08
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 8, 2014
______________________
RBC Life Sciences, Inc.
______________________
(Exact name of registrant as specified in its charter)
_______
NEVADA
_______
(State or other jurisdiction
of incorporation)
_______
000-50417
_________
(Commission
File Number)
_______
91-2015186
________
(IRS Employer
Identification No.)
2301 CROWN COURT, IRVING, TEXAS
(Address of principal executive offices)
____________
75038
_____________
(Zip Code)
Registrant's telephone number, including area code __________
972-893-4000
______________
__________________________
N/A
____________________________
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On January 8, 2014, RBC Life Sciences, Inc. (the "Company) and Richard S. Jablonski entered into an Employment Agreement (the "Jablonski Agreement") providing for compensation and related benefits to Mr. Jablonski in connection with his employment as Vice President - Finance and Chief Financial Officer of the Company.  Under the Jablonski Agreement, Mr. Jablonski will receive an annualized base salary of $200,000 and will be eligible to participate in any discretionary cash incentive plan which may be adopted by the Compensation Committee of the Company's Board of Directors.  In addition, Mr. Jablonski will receive a supplemental benefit payment of $1,000 each month for the term of the Jablonski Agreement.
The Jablonski Agreement is for an initial term beginning on January 1, 2014 and ending on December 31, 2014.  The term of the Jablonski Agreement will be automatically renewed for an additional one-year term upon expiration of the initial term and each subsequent term thereafter, unless either the Company or Mr. Jablonski gives written notice to the other party at least thirty (30) days prior to the last day of the then current term of the Jablonski Agreement. Upon termination of Mr. Jablonski's employment by the Company without Cause, by Mr. Jablonski for Good Reason (as such terms are defined in the Jablonski Agreement), or by non-renewal of the Jablonski Agreement by the Company, Mr. Jablonski shall be paid an amount equal to the greater of his monthly base salary through the last day of the then current term, or his monthly base salary for a period of six (6) months, plus a lump sum payment equal to his accrued, unused vacation and personal time off, not to exceed 520 hours.  For 12 months following the termination of his employment by the Company or in the event the Company elects not to renew the Jablonski Agreement, Mr. Jablonski will be prohibited from attempting to solicit the Company's existing customers and employees.
On January 8, 2014, the Company and Kevin B. Young entered into an Employment Agreement (the "Young Agreement") providing for compensation and related benefits to Mr. Young in connection with his employment as Vice President of Sales of the Company.  Under the Young Agreement, Mr. Young will receive an annualized base salary of $160,000 and will be eligible  to participate in any discretionary cash incentive plan which may be adopted by the Compensation Committee of the Company's Board of Directors.
The Young Agreement is for a term beginning on January 1, 2014 and ending on December 31, 2014.  Upon termination of employment by the Company without Cause or by Mr. Young for Good Reason (as such terms are defined in the Young Agreement), Mr. Young shall be entitled to receive his monthly base salary for a period of three months and a lump sum payment equal to his accrued, unused vacation and personal time off, not to exceed 520 hours.  For 12 months following the termination of his employment by the Company or in the event the Company elects not to renew the Young Agreement, Mr. Young will be prohibited from attempting to solicit the Company's existing customers and employees.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
January 9, 2014
RBC Life Sciences, Inc.
By:
/s/ Richard S. Jablonski
Name:  Richard S. Jablonski
Title:  Vice President - Finance & Chief Financial Officer